Pneumococcal AMC receives offers

in page functions

Four suppliers have made offers to supply vaccines under the Pneumococcal AMC

Geneva, 12 October 2009 - The AMC Secretariat is pleased to announce that four suppliers have made offers to supply vaccines under the Pneumococcal Advance Market Commitment.

The AMC concept was developed to create a healthy vaccine market.

Julian Lob-Levyt, CEO, GAVI Alliance

AMC donor group

The positive news was welcomed by the AMC donor group which consists of the governments of Italy, the UK, Canada, Norway, the Russian Federation and the Bill and Melinda Gates Foundation. Collectively, the group committed US$ 1.5 billion to speed up the introduction of life-saving pneumococcal vaccines that are appropriate and affordable for low-income countries.

"The AMC concept was developed to create a healthy vaccine market," said GAVI Alliance CEO Julian Lob-Levyt. "The news of these offers is very exciting because industry's participation demonstrates initial proof of the AMC concept."

Unprecedented opportunity

The pneumococcal AMC offers an unprecedented opportunity for low-income countries to protect their children from pneumococcal disease, the number one vaccine-preventable killer in children under five. It is estimated that introduction of the vaccine through the GAVI Alliance will save approximately seven million lives by 2030.

In the next two months, UNICEF's Supply Division will carefully evaluate the offers. Candidate vaccines will be assessed by an independent assessment committee and must meet the Pneumococcal AMC Target Product Profile (TPP). Supply agreements with manufacturers are expected to be signed by early 2010.

US$ 1 = US$ 18

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

More facts...

close icon

modal window here